Regeneron Pharmaceuticals took a modest hit as BDF Gestion reduced its stake by 11.5% in the first quarter, now holding $2.8 ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The stock's fall snapped a two-day winning streak.

Pallas Capital Advisors jumped into the biotech game by purchasing $426,000 worth of Regeneron Pharmaceuticals shares during ...

UnitedHealth Group ( UNH -1.61%) was the worst-performing stock in the S&P 500 last month. It plunged 26.6% to 52-week lows of $248.88 per share on May 15 after CEO Andrew Witty abruptly resigned and ...

Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...

This was the stock's second consecutive day of gains.

Zacks.com users have been paying close attention to JPMorgan Chase & Co. (JPM). This makes it worthwhile to examine what the stock has in store.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...